GE Healthcare tops its C-Pro cell processing system with SpinOculation, an automation software that enables closed T cells transduction at the preferred volume and concentration.
GE Healthcare opens lab space to provide developers with access to protein and cell analysis technologies to encourage networking and partnering on R&D services.
GE Healthcare’s Edison platform collaborates with ACR AI-Lab to extend its AI capabilities and allows ACR members access to algorithm creation in an aim to turn research into product development.
Stem Cell Theranostics has secured rights to the technology it uses to make cellular heart disease models for drug development through a deal with GE Healthcare.
GE Healthcare says new cell science lab in Wales will save drugmakers time and money and create more accurate alternatives to animal-based drug toxicity testing models.
GE Healthcare says its new range of sample collection cards reduce sample volumes needed for drug metabolism across pharmacokinetics (DMPK) in all stages of drug development process.
GE Healthcare Life Sciences division has launched a free-of-charge
one-stop shop for all life science purchases, regardless of
supplier, to give customers greater control over the ordering
process.
General Electric has completed its €8.1 billion acquisition of UK
healthcare company Amersham, promising to create a new company that
will 'change the face of healthcare,' according to GE chief
executive Jeffrey Immelt.
General Electric's €8.1 billion acquisition of the UK's Amersham
was approved by the European Union yesterday, after it concluded
that the deal would not create a monopoly in Europe's medical
imaging market.
General Electric is the company offering to buy Amersham of the UK,
it was confirmed today. The US group is offering £5.7 billion for
the life sciences group, and said it has no plans to hive off
Biosciences.
